T. Rowe Price Investment Management, Inc. 13D and 13G filings for Ascendis Pharma A/S:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-07 11:03 am Purchase | 2026-04-30 | 13G | ASCENDIS PHARMA A/S SPONSORED ASND | T. Rowe Price Investment Management, Inc. | 6,506,219 10.500% | 344,177 (+5.59%) | Filing |
| 2026-05-07 10:32 am Purchase | 2026-03-31 | 13G | ASCENDIS PHARMA A/S SPONSORED ASND | T. Rowe Price Investment Management, Inc. | 6,162,042 9.900% | 3,494,479 (+131.00%) | Filing |
| 2025-11-14 12:18 pm Sale | 2025-09-30 | 13G | ASCENDIS PHARMA A/S SPONSORED ASND | T. Rowe Price Investment Management, Inc. | 2,667,563 4.800% | -915,983 (-25.56%) | Filing |
| 2025-08-14 12:12 pm Purchase | 2025-06-30 | 13G | ASCENDIS PHARMA A/S SPONSORED ASND | T. Rowe Price Investment Management, Inc. | 3,583,546 6.400% | 529,722 (+17.35%) | Filing |
| 2025-05-14 10:47 am Purchase | 2025-03-31 | 13G | ASCENDIS PHARMA A/S SPONSORED ASND | T. Rowe Price Investment Management, Inc. | 3,053,824 5.000% | 1,288,782 (+73.02%) | Filing |
| 2024-11-14 1:28 pm Sale | 2024-09-30 | 13G | ASCENDIS PHARMA A/S SPONSORED ASND | T. Rowe Price Investment Management, Inc. | 1,765,042 2.900% | -2,224,788 (-55.76%) | Filing |
| 2024-02-14 10:04 am Purchase | 2023-12-31 | 13G | ASCENDIS PHARMA A/S SPONSORED ASND | T. Rowe Price Investment Management, Inc. | 3,989,830 6.900% | 3,989,830 (New Position) | Filing |